Literature DB >> 11754987

Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence.

P P Zandi1, J C Breitner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11754987     DOI： 10.1016/s0197-4580(01)00297-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


× No keyword cloud information.
  19 in total

1.  The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study.

Authors:  K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin
Journal:  Exp Gerontol       Date:  2011-09-24       Impact factor: 4.032

Review 2.  Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

Authors:  Todd E Golde
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

Review 3.  Association Between Non-Steroidal Anti-Inflammatory Drug Use and Cognitive Decline: A Systematic Review and Meta-Analysis of Prospective Cohort Studies.

Authors:  WeiJing Wang; YanPing Sun; DongFeng Zhang
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

4.  Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity.

Authors:  Linda A Kotilinek; Marcus A Westerman; Qinwen Wang; Kimberly Panizzon; Giselle P Lim; Agnes Simonyi; Sylvain Lesne; Agnieszka Falinska; Linda H Younkin; Steven G Younkin; Michael Rowan; James Cleary; Roi Ann Wallis; Grace Y Sun; Greg Cole; Sally Frautschy; Roger Anwyl; Karen H Ashe
Journal:  Brain       Date:  2008-03       Impact factor: 13.501

Review 5.  Inflammation in central nervous system injury.

Authors:  Stuart M Allan; Nancy J Rothwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-10-29       Impact factor: 6.237

6.  Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.

Authors:  Adam D Bachstetter; Christopher M Norris; Pradoldej Sompol; Donna M Wilcock; Danielle Goulding; Janna H Neltner; Daret St Clair; D Martin Watterson; Linda J Van Eldik
Journal:  J Neurosci       Date:  2012-07-25       Impact factor: 6.167

Review 7.  Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.

Authors:  Todd E Golde
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

8.  Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease.

Authors:  Uzma A Chaudhry; Hean Zhuang; Barbara J Crain; Sylvain Doré
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

9.  Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease.

Authors:  Amber Watts; Eileen M Crimmins; Margaret Gatz
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

10.  Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression.

Authors:  D Martin Watterson; Anastasia V Velentza; Magdalena Zasadzki; Jeffrey M Craft; Jacques Haiech; Linda J Van Eldik
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.